Skip to Content

Neoadjuvant nivolumab + chemotherapy improved pathological complete response rate regardless the stage of NSCLC

New analyses of CheckMate-816 show that neoadjuvant nivolumab in combination with platinum-doublet chemotherapy did not compromise tumor resection outcome and significantly improved pathological complete response rate compared to chemotherapy alone in patients with resectable non-small cell lung cancer.

Woman with cancer looking at x-ray

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top